NCT02483208View on ClinicalTrials.gov

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

December 31, 2015

Conditions
Hemophilia A
Interventions
DRUG

BAY81-8973

BAY81-8973 infusion to analyze pharmacokinetics

DRUG

Advate

Advate infusion to analyze pharmacokinetics.

Trial Locations (1)

1756

Sofia

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY